15 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Article Searches
The AI Race Gets Litigious https://www.fool.com/investing/2024/03/09/the-ai-race-gets-litigious/?source=iedfolrf0000001 Mar 09, 2024 - We've also got a look at the role of patents in pharmaceuticals and the "patent cliff" looming over the next decade.
Gilead (GILD) Down as NSCLC Study Fails to Meet Primary Goal https://www.zacks.com/stock/news/2214367/gilead-gild-down-as-nsclc-study-fails-to-meet-primary-goal?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2214367 Jan 23, 2024 - Gilead Sciences' (GILD) phase III study evaluating Trodelvy (sacituzumab govitecan) in previously treated metastatic NSCLC fails to meet its primary endpoint. Shares decline on the same.
Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More https://www.zacks.com/stock/news/2223529/biotech-stock-roundup-gild-amgn-bmy-s-q4-results-mor-up-on-nvs-deal-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2223529 Feb 08, 2024 - Earnings of Gilead (GILD) and Amgen (AMGN) are in focus in the biotech sector.
Gilead (GILD) to Buy CBAY for $4.3B, Add PBC Drug to Pipeline https://www.zacks.com/stock/news/2225414/gilead-gild-to-buy-cbay-for-4-3b-add-pbc-drug-to-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2225414 Feb 13, 2024 - Gilead (GILD) is all set to acquire CymaBay Therapeutics for $4.3 billion and strengthen its liver disease portfolio with the addition of seladelpar to its pipeline.
Where Are Biotech ETFs Headed After Q4 Earnings? https://www.zacks.com/stock/news/2226390/where-are-biotech-etfs-headed-after-q4-earnings?cid=CS-ZC-FT-etf_news_and_commentary-2226390 Feb 14, 2024 - Look into how Biotech ETFs performed after Q4 earnings.
Gilead (GILD), Compugen Collaborate for Immunotherapy Program https://www.zacks.com/stock/news/2200585/gilead-gild-compugen-collaborate-for-immunotherapy-program?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200585 Dec 20, 2023 - Gilead (GILD) enters into a license agreement with Compugen for its pre-clinical immunotherapy program.
Biotech Stock Roundup: CGEN Up on GILD Deal, MRNA Gains on Study Data & More https://www.zacks.com/stock/news/2201158/biotech-stock-roundup-cgen-up-on-gild-deal-mrna-gains-on-study-data-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2201158 Dec 21, 2023 - Compugen (CGEN) and Moderna (MRNA) are in the news on collaboration and study updates, respectively.
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know https://www.zacks.com/stock/news/2206596/gilead-sciences-gild-stock-falls-amid-market-uptick-what-investors-need-to-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2206596 Jan 05, 2024 - In the most recent trading session, Gilead Sciences (GILD) closed at $83.31, indicating a -1.38% shift from the previous trading day.
Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts https://www.zacks.com/stock/news/2211770/gilead-sciences-gild-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2211770 Jan 17, 2024 - In the closing of the recent trading day, Gilead Sciences (GILD) stood at $86.48, denoting a +0.57% change from the preceding trading day.
Biotech Stock Roundup: GILD Down on Study Results, INBX Gains on Sanofi Deal & More https://www.zacks.com/stock/news/2215085/biotech-stock-roundup-gild-down-on-study-results-inbx-gains-on-sanofi-deal-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2215085 Jan 24, 2024 - Gilead Sciences (GILD) and Inhibrx (INBX) are in the spotlight on regulatory and pipeline updates.

Pages: 12

Page 1